Burning Rock Biotech Limited (BNR)
| Previous close | 0.8500 |
| Open | 0.8142 |
| Bid | 0.5950 x 200 |
| Ask | 1.0500 x 200 |
| Day's range | 0.7819 - 0.8784 |
| 52-week range | 0.5720 - 3.2500 |
| Volume | |
| Avg. volume | 48,966 |
| Market cap | 87.294M |
| Beta (5Y monthly) | 0.23 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.9500 |
| Earnings date | 28 May 2024 - 03 June 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 3.95 |
GlobeNewswireBurning Rock Announces ADS Ratio Change
GUANGZHOU, China, April 26, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it will change the ratio of its American depositary shares (the “ADSs”) to Class A ordinary shares from one (1) ADS representing one (1) Class A ordinary share to one (1) ADS representing ten (10) Class A ordinary sh
- Thomson Reuters StreetEvents
Q4 2023 Burning Rock Biotech Ltd Earnings Call
Q4 2023 Burning Rock Biotech Ltd Earnings Call
- GlobeNewswire
Burning Rock Reports Fourth Quarter and Full Year 2023 Financial Results
GUANGZHOU, China, March 28, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months and the year ended December 31, 2023. 2023 Business Overview and Recent Updates Corporate Updates Completed profitability-driven organizational optimization, execution towards profita
